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Abstract
Background: Pterodon pubescens Benth seeds are commercially available in the Brazilian medicinal plant street
market. The crude alcoholic extracts of this plant are used in folk medicine as anti-inflammatory, analgesic, and
anti-rheumatic preparations. The aim of this study was to evaluate the contribution of geranylgeraniol (C1) and 6a,
7b-dihydroxyvouacapan-17b-oate methyl ester (C2) isolated from Pterodon pubescens Benth. to the antinociceptive
activity of the crude extract.
Results: Compounds C1 and C2 demonstrated activity against writhing with intraperitoneal (i.p.) and oral (p.o.)
routes, capsaicin (i.p. and p.o.), glutamate (i.p.), and in the hot-plate (p.o.) tests, demonstrating their contribution to
the antinociceptive activity of crude Pterodon pubescens Benth extracts. The observed activity of compounds C1
and C2 may be related to vanilloid receptors VR1, and/or glutamate peripheral receptors. In hot-plate model, the
antinociceptive activity was maintained when naloxone chloride (opioid antagonist) was administered prior to
treatment with compounds suggesting that C1 and C2 (p.o.) do not exert their antinociceptive effects in the hot-
plate test via opioid receptors. The findings presented herein also suggest that compounds within the crude
Pterodon pubescens Benth. extract may exert a synergistic interactive effect, since the crude extract (300 mg.kg
-1)
containing lower concentrations of compounds C1 (11.5%- 34.6 mg. kg
-1) and C2 (1.5% - 4.7 mg.kg
-1) gave
statistically the same effect to the pure compounds when tested separately (C1 = C2 = 300 mg.kg
-1) in writhing
experimental model with p.o. administration. Further studies will be undertaken to establish more specifically the
mechanisms of action for compounds C1 and C2. Possible synergistic interactions will be evaluated employing the
Isobole method.
Conclusion: These results allowed us to establish a relationship between the popular use of Pterodon pubescens
seeds for pain relief and the activity of two major compounds isolated from this species which demonstrated
antinociceptive activity. Various “in vivo” experimental models corroborate the folk use of this species for different
pain and inflammation disorders.
Background
Pterodon pubescens
Benth. (Leguminosae), known as sucupira, is widespread
throughout the Brazilian states of Goiás, Minas Gerais
and São Paulo. Sucupira seeds are commercially avail-
able in the Brazilian medicinal plant market. The crude
alcoholic extracts of this plant are used in folk medicine
as anti-inflammatory, analgesic and anti-rheumatic pre-
parations [1,2]. Phytochemical studies of the Pterodon
genus have shown the presence of alkaloids, isoflavones
and diterpenes. Furanditerpenes were identified and iso-
lated from Pterodon fruits [3-7]. Studies have suggested
that furanditerpenes possessing the vouacapan skeleton
contribute to the anti-inflammatory and antinociceptive
properties of Pterodon pubescens seed oil [8-12]. Diter-
penes 6a-hydroxyvouacapan-7b-17b-lactone and 6a,7 b-
dihydroxyvouacapan-17b-oate methyl ester, found in P.
emarginatus and P. polygalaeflorus seeds were
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inflammatory activity of these species [8]. Herein we
report the antinociceptive activity of 6a,7 b-dihydroxy-
vouacapan-17b-oate methyl ester and geranylgeraniol
isolated from Pterodon pubescens Benth. when evaluated
in writhing, capsaicin, glutamate and hot-plate animal
experimental models.
Results and Discussion
Some authors have reported the antinociceptive activity
of the crude extract and fractions obtained from P. pub-
escens and established a relationship with anti-inflamma-
tory activity [10,12]. This report evaluated for the first
time the contribution of geranylgeraniol (C1) and 6a,
7b-dihydroxyvouacapan-17b-oate methyl ester (C2), iso-
lated from P. pubescens (Fig. 1), to the antinociceptive
activity using various experimental models to evaluate a
distinct pain modulation.
Calixto et al [13] demonstrated the antiplatelet activity
of geranylgeraniol attributed to cyclooxygenase enzyme
inhibition, but did not mention data on antinociceptive
activity. Some vouacapan compounds have been sug-
gested to have a relationship with P. pubescens’ antinoci-
ceptive activity. Neverthele s sp a i nm o d u l a t i o nb yt h i s
species has never been reported, being described herein
for the first time. The following screening results
demonstrated the activity and general mechanisms
involved in antinociception caused by geranylgeraniol
(C1) and 6a,7 b-dihydroxyvouacapan-17b-oate methyl
ester (C2).
The most relevant additional findings of the present
work are that, (i) compounds C1 and C2 may present
synergistic activity; (ii) both intraperitoneal (i.p.) and
oral (p.o.) treatment of compounds C1 and C2 reduced
reactivity to the writhing test demonstrating differ-
ences in potency related to the route of administration;
(iii) both compounds C1 and C2 demonstrated possible
activity related to vanilloid receptors and/or glutamate
peripheral receptors, with C2 being more potent by
the i.p. route; (iv) the antinociceptive activity of com-
pounds C1 and C2 (p.o.) do not appear to exert their
antinociceptive effects in the hot-plate test via opioid
receptors.
Initially, the open field test was performed in order to
exclude the possibility that the antinociceptive action of
geranylgeraniol (C1) and 6a,7 b-dihydroxyvouacapan-
17b-oate methyl ester (C2) could be related to non-spe-
cific disturbances in the locomotor activity of the
animals. Treatment with compounds C1 and C2 (30 mg.
kg
-1, i.p.) did not cause any significant change in the
ambulation of mice when tested in the open field. How-
ever, pentobarbital (35 mg.kg
-1,i . p . )s i g n i f i c a n t l y( p<
0.001) reduced the locomotor activity of animals in this
test. The mean number of crossings was 48.2 ± 2.2, 13.7
±6 . 1 ,5 0±4 . 4a n d4 2±3 . 6f o rv e h i c l e ,p e n t o b a r b i t a l ,
C1 and C2, respectively.
After these results, the acetic acid writhing test model
was employed. This is a convenient stimulus assay for
screening, because the intensity of response depends on
the interaction of several factors, neurotransmitters and
neuromodulators that determine nociception, such as
kinines, acetylcholine, substance P and prostaglandins.
Therefore, this model is responsive to analgesic sub-
stances possessing with the most varied action mechan-
isms [14,15], being sensitive to drugs with analgesic
activity such as aspirin, kinin receptor antagonists (bra-
dykinin, kallidin or T-kinin) and opioid analgesics with
central or peripheral action [16,17]. This model per-
mitted evaluation of antinociceptive activity caused by
both neurogenic and/or inflammatory pain. This assay
was used during the initial studies with compounds C1
and C2 in order to establish differences in potency
using different routes of administration.
The antinociceptive activity of compounds C1 and C2
were compared with the dichloromethane extract (EB)
(p.o.) in the writhing test using 300 mg.kg
-1 doses. The
reductions in the number of abdominal constrictions
were 62%, 64% and 66% for EB, C1 and C2 respectively
(p ≤ 0.001) (not shown). These results suggested a possi-
ble synergistic activity among compounds C1 and C2
[these compounds are only at concentration: C1
(11.56%- 34.6 mg. kg
-1) and C2 (1.58% - 4.7 mg.kg
-1)i n
the EB fraction]. Accordingly, dose-response curves for
i.p. and p.o. administered compounds were determined
in the writhing test to calculate ED50 values and possible
differences caused by administration routes.
Figure 1 Chemical structures of compounds A) 6a,7 b-
dihydroxyvouacapan-17b-oate methyl ester (C2), and B)
Geranylgeraniol (C1).
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dose-related activity reducing by 51%, 57%, and 75% (p
≤ 0.01) the abdominal constrictions with 30 mg.kg
-1,
100 mg.kg
-1, and 300 mg.kg
-1 doses respectively, pre-
senting ED50 =2 6 . 7m g . k g
-1 (Fig. 2). The same treat-
ment with compound C2 reduced constrictions by 43%
(100 mg.kg
-1) and 71% (300 mg.kg
-1)w i t hE D 50 = 35.6
mg.kg
-1. These results showed that compound C1 was
more potent than C2 when given by p.o. administration.
The dose-related activity for compounds administered i.
p. (systemic route) in the writhing test, demonstrated
that compound C1 reduced constrictions by 58% and
98% (p ≤ 0.001) with 100 mg.kg
-1 and 300 mg.kg
-1 doses
respectively (ED50 =2 2 . 4m g . k g
-1) (Fig. 3). Compound
C2 reduced constrictions by 84%, 90%, and 98% with 30
mg.kg
-1,1 0 0m g . k g
-1,a n d3 0 0m g . k g
-1 doses respec-
tively, showing ED50 = 11.5 mg.kg
-1,m o r ep o t e n tt h a n
C1. In the i.p. tests, the numbers of abdominal constric-
tions of the control group were fewer compared to the
control group of the p.o. route, maybe caused by injec-
tion-stress of the animals.
In order to evaluate the antinociceptive response of
compounds C1 and C2 in neurogenic pain caused by
direct chemical stimulation on nociceptors, the capsaicin
test was evaluated. The active principle, Capsaicin, from
Capsicum genus peppers, is the painful substance used
to determine if compounds possessing antinociceptive
activity act by the vanilloid VR1 receptors. The animal
response is caused by release of neuropeptides, such as
substance P, neurokinines, somastotastin, peptide related
to the calcitonin gene (CGRP) with participation of
nociceptive afferent C fibers, and in part, A fibers
[18,19]. The induced nociceptive process with capsaicin
is related to the activation of the tachykininergic system
and seems to be mediated by activation of a specific
receptor, whose presence has been confirmed with cap-
sazepine, a competitive vanilloid antagonist. Evidence
also suggests that bradykinin (BK) acting through B2
receptors seems to be involved in the neurogenic noci-
ception caused by capsaicin in mice [20].
In this test, i.p. administration of compound C1
reduced by 43%, 48%, 58%, and 67% (p ≤ 0.01) with 10
mg.kg
-1, 30 mg.kg
-1, 100 mg.kg
-1, and 300 mg.kg
-1 doses
respectively (ED50 =3 4 . 1m g . k g
-1) (Fig. 4). Compound
C2 showed dose-related activity too, reducing by 51%,
56%, 66%, and 69% (p ≤ 0.01) the reaction time, with 10
mg.kg
-1, 30 mg.kg
-1, 100 mg.kg
-1, and 300 mg.kg
-1 doses
respectively (ED50 = 27.8 mg.kg
-1). These results showed
that the antinociceptive activity of compounds C1 and
C2 may be related to the tachykininergic system or
vanilloid VR1 receptors. The same experimental model
was tested with p.o. administration of compounds C1
Figure 2 Abdominal constrictions induced by acetic acid (0.8% in saline) in mice previously administered (60 min) p.o. with control
vehicle (10 mL.kg
-1), or compounds C1 and C2 (dose-response). Results expressed as mean ± SEM of up to 8 animals for experimental
groups (*p ≤ 0.05; **p ≤ 0.01).
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-1)a n dC 2( 3 0 0m g . k g
-1) employing mor-
phine (20 mg.kg
-1) as positive control, in order to evalu-
a t et h ea c t i v i t yo fc o m p o u n d so nt h i sr o u t e( F i g .5 ) .
Compound C2 reduced reaction time by 82% whereas
C1 reduced by 65%, with the positive control demon-
strating reduction by 52% (p ≤ 0.001). This assay
demonstrated that compound C2 was more potent in
neurogenic pain modulated by vanilloid receptors than
compound C1, corroborating the previous result with
intraperitoneal administration.
Once we had demonstrated the activity of compounds
geranylgeraniol (C1) and 6a,7b-dihydroxyvouacapan-17b-
oate methyl ester (C2) with the writhing and capsaicin
tests, we considered the glutamate test. This model is
based on the activation of peripheral glutamate receptors
responsible for several types of pain sensation. The noci-
ceptive response induced by glutamate appears to involve
peripheral, spinal and supraspinal sites of action and is
mediated by both NMDA and non-NMDA receptors as
well as by the release of nitric oxide or by some nitric
oxide-related substances. Nitric oxide inhibitors and both
NMDA and non-NMDA receptor antagonists, and other
drugs have been previously reported to inhibit the acetic-
acid and capsaicin- induced nociceptive response [21].
Our results showed that i.p. administration of com-
pounds C1 and C2 produced a significant dose-related
inhibition of the nociceptive response caused by intra-
plantar injection of glutamate into the mouse’sh i n d
paw. In this test, the p.o. route was not evaluated
because of possible changes of pharmacokinetic, meta-
bolic or distribution parameters, which could disrupt
the interaction among compounds and receptors (con-
sidering the wide receptors distribution). Compound C1
(i.p.), with 10 mg.kg
-1,3 0m g . k g
-1,1 0 0m g . k g
-1, and 300
mg.kg
-1 doses reduced reaction time by 67%, 72%, 75%,
and 80% respectively (p ≤ 0.001), corresponding to on
ED50 = 57.4 mg.kg
-1 (Fig. 6). Compound C2 (i.p.)
showed ED50 = 35.1 mg.kg
-1, reducing by 62%, 83%, and
96% the reaction time with 30 mg.kg
-1, 100 mg.kg
-1, and
300 mg.kg
-1 doses (p ≤ 0.001) respectively (Fig. 7), again
more potent than C1 in peripheral neurogenic modula-
tion. Thus, these previous findings and the present
results suggested that the antinociceptive action of com-
pounds C1 and C2 in the acetic acid, capsaicin, and glu-
tamate tests could be the result of both the inhibition of
NOS and the blockade of glutamate receptors. Further
studies are being undertaken to confirm receptors
involved on this activity.
Figure 3 Abdominal constrictions induced by acetic acid (0.8% in saline) in mice previously administered (30 min) i.p. with control
vehicle (10 mL.kg
-1), or compounds C1 and C2 (dose-response). Results expressed as mean ± SEM of up to 8 animals for experimental
groups (**p ≤ 0.01; ***p ≤ 0.001).
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Page 4 of 10Figure 4 Reactivity time to the intraplantar application of capsaicin (1.6 μg.paw
-1) in the hind paw of mice previously treated (30 min)
i.p. with control vehicle (10 mL.kg
-1), or compounds C1 and C2 (dose-response curve). Results expressed as mean ± SEM of up to 8
animals for experimental groups (* p ≤ 0.05; ** p ≤ 0.01).
Figure 5 Reactivity time to the intraplantar application of capsaicin (1.6 μg.paw
-1) in the hind paw of mice previously treated (30 min)
p.o. with control vehicle (10 mL.kg
-1), morphine (20 mg.kg
-1) or compounds C1 and C2 (300 mg.kg
-1). Results expressed as mean ± SEM
of up to 8 animals for experimental groups (***p ≤ 0.001).
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Page 5 of 10Figure 6 Reactivity time to the intraplantar application of glutamate (10 μmol.paw
-1) in the hind paw of mice previously treated (30
min) i.p. with control vehicle (10 mL.kg
-1) or compound C1 (dose-response curve). Results expressed as mean ± SEM of up to 8 animals
for experimental groups (**p ≤ 0.01 ***p ≤ 0.001).
Figure 7 Reactivity time to the intraplantar application of glutamate (10 μmol.paw
-1) in the hind paw of mice previously treated (30
min) i.p. with control vehicle (10 mL.kg
-1) or compound C2 (dose-response curve). Results expressed as mean ± SEM of up to 8 animals
for experimental groups (**p ≤ 0.01 ***p ≤ 0.001).
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thermal nociception model by p.o. route. This route was
chosen based on preliminary set of experiments which
showed to induce less stress to animals. The hot-plate
test is a neurogenic-modulated model that produces, at
constant temperature, two kinds of behavioral response,
which are paw licking and jumping. Both of these are
considered to be supraspinally- integrated responses [22].
In order to evaluate the antinociceptive activity of com-
pounds C1 and C2 mediated by opioid receptors, the hot
plate test was carried out using the opioid antagonist
naloxone hydrochloride. The p.o. doses for compounds
C1 and C2 were chosen based on preliminary studies in
our laboratory. Pre-treatment with naloxone (1 mg.kg
-1),
did not reverse the antinociceptive effect of both com-
pounds when the animals were treated p.o. with 100 mg.
kg
-1 doses (p ≤ 0.001), especially at 60 minutes after chal-
lenge, suggesting that these compounds do not possess
similar action to morphine or derivatives when evaluated
in this assay (Table 1).
Conclusion
Both i.p. and p.o. treatment with compounds C1 and C2
reduced response in the writhing, Capsaicin, Glutamate,
and hot-plate tests demonstrating their contribution to
the antinociceptive activity of crude Pterodon pubescens
Benth extracts.
Compounds, C1 and C2, demonstrated activity in
models demonstrative of vanilloid receptors and gluta-
mate peripheral receptors. In the hot-plate model, the
antinociceptive activity was maintained when naloxone
hydrochloride, an opioid antagonist, was administered
prior to sample dosing suggesting that compounds C1
and C2 do not exert their antinociceptive effects in the
hot-plate test via opioid receptors.
The findings presented herein also suggested that
crude Pterodon pubescens Benth extract probably is a
mixture of substances with synergistic interactive effect,
since the crude extract (300 mg.kg
-1) with lower concen-
trations of compounds C1 (11.5%- 34.6 mg. kg
-1)a n d
C2 (1.5% - 4.7 mg.kg
-1) presented statistically analogous
effects to those of the pure compounds when tested
separately (C1 = C2 = 300 mg.kg
-1) with p.o. administra-
tion in the writhing experimental model.
Further studies will be undertaken to establish the
mechanisms of action for compounds C1 and C2. The
synergistic interactions will be evaluated employing the
Isobole method [23].
Methods
4.1. Plant Material
Seeds were collected in Pedregulho (SP) and São Carlos
(SP) cities, in March 2004. Prof. Dr. Jorge Yoshio Tama-
shiro from IB-UNICAMP (Department of Botany) iden-
tified the plant species. A voucher specimen was
Table 1 Time elapsed (sec.) for nociceptive response in Hot Plate Test in mice related to the time of experiment.
Treatment Time elapsed after treatment (means ± SD)/
Increase in response time compared to control (%)
N 0 min 30 min 60 min 90 min 120 min
Control 7 3.4 ± 1.2 3.4 ± 1.5 NS 5.2 ± 0.92 NS 7.04 ± 0.75 NS 6.0 ± 0.95 NS
Morphine 20
mg.kg
-1
6 2.07 ± 0.65 6.9 ± 0.76 203%** 8.15 ± 1.52 163.5%* 13.35 ± 4.05 189.6%** 6.8 ± 2.11 NS
Naloxone 1
mg.kg
1/
control
6 3.0 ± 0.39 4.72 ± 0.77 NS 5.3 ± 0.7 NS 6.25 ± 1.23 NS 6.65 ± 0.9 NS
Naloxone 1
mg.kg
1/
Morphine20
mg.kg
1
8 3.6 ± 1.12 4.81 ± 1.42 NS 7.07 ± 2.23 NS 5.2 ± 1.53 NS 6.0 ± 1.27 NS
C2 100 mg.kg
-
1
8 3.5 ± 1.0 4.88 ± 2.21 NS 12.35 ± 1.24 237.5%** 11.5 ± 2.77 163.4%** 7.38 ± 0.76 NS
Naloxone1
mg.kg
1/C2
100 mg.kg
1
7 3.4 ± 1.2 4.21 ± 1.8 NS 11.5 ± 2.11 221.2%** 9.41 ± 2.69 NS 6.65 ± 2.8 NS
C1 100 mg.kg
-
1
8 3.1 ± 1.2 6.16 ± 2.0 179%** 10.66 ± 2.13 205%** 8.98 ± 1.48 NS 9.2 ± 2.4 153.3%**
Naloxone1
mg.kg
1/C1
100 mg.kg
1
8 3.5 ± 1.3 5.0 ± 1.68 NS 13.42 ± 2.24 258%** 12.06 ± 2.27 171.3%** 6.7 ± 2.12 NS
Statistical Analysis ANOVA
DUNCAN’S Test: *p < 0.05; **p < 0.01
NS: no significant result
Morphine, Naloxone, C1, C2 and vehicle given orally.
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Herbarium, under number 1398.
4.2. Compound Isolation
Freeze-dried Seeds (100 g) were ground prior to use in
a Stephen mill (model UM 40) and extracted with
dichloromethane at room temperature yielding 32%
extractable. A portion of the crude dichloromethane
extract (32 g) was chromatographed over silica gel
(192 g) and eluted sequentially with hexane [F1] (3 ×
150 ml); hexane/ethyl acetate 5% [F2] (3 × 150 mL);
hexane/ethyl acetate 15% [F3] (3 × 150 mL); ethyl
acetate (3 × 150 mL) [F4]; methanol (3 × 150 mL)
[F5]. The crude extract fractions were monitored by
thin layer chromatography (TLC), visualized with ani-
saldehyde reagent (50 mL acetic acid, 0.5 mL sulfuric
acid and 0.5 mL anisaldehyde) followed by heating at
110°C. Similar fractions were grouped according to
their thin layer chromatography profile. Antinocicep-
tive assay indicated that fractions F3 and F4 (10 g)
showed activity and they were successively chromato-
graphed by CC on silica-gel (70-230 mesh) (5 × 60
cm) providing 6a,7 b-dihydroxyvouacapan-17b-oate
methyl ester and geranylgeraniol with spectral data
(FTIR,
1Ha n d
13CN M Rd a t a )i na c c o r d a n c ew i t h
those reported previously [7].
4.3. Chromatographic analysis
The GC/MS analysis was carried out using a HP-6890/
5975 system equipped with a J&W Scientific DB-5 fused
capillary column (25 m × 0.2 mm × 0.33 m). Tempera-
ture program: 60°C (5°C min
-1) - 300°C (10 min.), injec-
tor 250°C, detector 300°C. Helium was used as carrier
gas (0.7 bar, 1 ml min
-1). The MS were taken at 70 eV.
Scanning speed was 0.84 scans s
-1, from 40 to 550. Sam-
ple volume was 1 μl. Split: 1:40.
Quantification of 6a,7 b-dihydroxyvouacapan-17b-oate
methyl ester and geranylgeraniol in crude P. pubescens
extract were obtained by internal standard method [24]
using butylphtalate as internal standard with authentic
6a,7 b-dihydroxyvouacapan-17b-oate methyl ester and
geranylgeraniol samples. Analysis determined 1.6% of
6a,7 b-dihydroxyvouacapan-17b-oate methyl ester (C2)
and 11.6% of geranylgeraniol (C1).
4.4. High-resolution eletrospray ionization mass
spectroscopy (HRESI-MS)
HRESI-MS was recorded on a Q-Tof Mass Spectrometer
(Micromass - U.K.) using direct infusion of a 10 μL.min
-
1 MeOH + 0,1% formic acid solution and ionization by
electrospray in the positive ion mode. Major operation
conditions were as follow: capillary voltage of 3.5 kV,
source temperature of 100°C, desolvation temperature of
100°C and cone voltage of 35 V.
4.5. Animals
Male Swiss mice with 25-35 g body weight were kept at
25 ± 2°C in 12 h light-dark cycles (light phase started at
7:00 am) maintained (10 animals per cage) with water
and food ad libitum, at least for 7 days prior to assays.
Animals were fasted 12 hours prior to oral administra-
tion of compounds, in order to avoid possible pharma-
cokinetic interactions. Separate groups of mice were
used for each analgesic test and route of administration,
and animals were used only once in experiments. Stu-
dies were carried out in accordance with current guide-
lines for the veterinary care of laboratory animals [25]
and were performed under the consent and surveillance
of Unicamp’s Institute of Biology Ethics Committee for
Animal Research (766-1).
4.6. Drugs
A l ld r u g sa n dc o m p o u n d sC 1a n dC 2w e r ed i l u t e di n
vehicle made of Tween
80 1% (Sigma-Aldrich, U.S.A) in
saline solution 0.9% (NaCl diluted in distilled water).
Reagents (capsaicin and glutamic acid) diluted in phos-
phate buffer solution (PBS, pH 6.8). The following drugs
and reagents were used: pentobarbital (Cristália- Brazil),
acetic acid, capsaicin, glutamic acid, naloxone hydro-
chloride (Sigma-Aldrich, U.S.A) and morphine hydro-
chloride (FHC, Brazil).
4.7. Evaluation of locomotor activity
The open-field test was used to exclude the possibility
that the antinociceptive action of compounds geranyl-
geraniol (C1) and 6a,7 b-dihydroxyvouacapan-17b-oate
methyl ester (C2) could be resultant from non-specific
disturbances in the locomotor activity of the animals.
The ambulatory behavior was assessed in an open-field
test as described previously [17] with few changes. The
apparatus consisted of a plastic box measuring 45 × 45
× 20 cm, with the floor divided into 9 equal squares (15
× 15 cm). The number of squares crossed with all paws
(crossing) was counted in a 3-min session. Mice were
treated intraperitoneally (i.p.) with compounds C1 and
C2 (30 mg.kg
-1, i.p.), pentobarbital (35 mg.kg
-1)o rv e h i -
cle 30 min beforehand. Results expressed as mean ± S.E.
M. of 4 animals per group.
4.8. Writhing test
The writhing test was carried out as described by Kos-
ter et al [26] with few changes. Groups of mice (n =8 )
were treated orally (p.o.) or i.p with vehicle (10 mL.kg
-
1) or compounds geranylgeraniol (C1) and 6a,7 b-dihy-
droxyvouacapan-17b-oate methyl ester (C2) using four
doses 10, 30, 100, and 300 mg.kg
-1 to determine ED50.
Dose-related results do not need positive control. Wri-
thing was induced by an i.p. injection of 0.8% acetic
acid solution (0.1 mL.10 g
-1), 30 or 60 min after treat-
ment (i.p. and p.o. respectively). After injection of the
acetic acid solution, the numbers of writhings (abdom-
inal constrictions) were cumulatively counted over 15
minutes, for nociception evaluation. Data represent the
average of the total writhing observed per dose
concentration.
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The procedure used was according to Santos and
Calixto [27] with few changes. Different groups of ani-
mals (n = 8) were treated p.o. with compounds C1 and
C2 (300 mg.kg
-1), morphine hydrochloride (20 mg.kg
-1),
or vehicle, or i.p. with compounds C1 and C2 (10, 30,
100, 300 mg.kg
-1)o rv e h i c l e .N on e e dt ou s ep o s i t i v e
control to determine ED50. After 60 or 30 minutes
(respectively), 50 μLo fc a p s a i c i n( 1 . 6μg.paw
-1 prepared
in PBS) was injected in the ventral surface of the right
hind paw. The time that the animals spent licking the
injected paw, for the first 5 minutes post capsaicin injec-
tion, was recorded with a chronometer and considered
as indicative of nociception.
4.10. Glutamate test
The glutamate test was carried out as described by Ell-
son et al [28] with adaptations. Different groups of ani-
mals (n = 8) were treated i.p. with compounds C1 and
C2 (10, 30, 100 and 300 mg.kg
-1) (dose- related to deter-
mine ED50). No need to use positive control to deter-
mine ED50. Animals received 20 μL of glutamate
solution (glutamic acid in PBS) 30 min after compound
treatment, injected intraplantar (i.pl.) in the ventral sur-
f a c eo fr i g h th i n dp a w( 1 0μmol.paw
-1), and were
observed individually for 15 min following glutamate
injection. The amount of time spent licking the injected
paw was chronometered and was considered as indica-
tive of nociception.
4.11. Hot Plate Test
The hot plate test was performed according to Woolfe
and Mac Donald (1944) [29]. Each animal group (n =
16) were treated p.o. with compounds C1 (100 mg.kg
-1),
C2 (100 mg.kg
-1), morphine hydrochloride (20 mg.kg
-1),
or vehicle, and a half of these groups (n =8 )w e r ep r e -
treated (20 min) p.o. with naloxone hydrochloride (1
mg.kg
-1) or vehicle (oral administration was used to
reduce the stress caused by injection), before thermal
algesic stimulation. Mice were placed on the hot plate
which was kept at 56°C ± 0.1°C, and the reaction time
was noted by observing either the licking of the hind
paws, jumping, or the rotation movements at 30, 60, 90,
and 120 minutes after administration. For this test, the
animals were selected 24 hs before using the same alge-
sic stimulation (cut off 20 sec.).
4.12. Statistical Analysis
All results were submitted to one way analysis of var-
iance (ANOVA), considering as critical level p ≤ 0.05 to
evaluate significant difference between the control and
treated groups, followed by Duncan’s Test, using Stat-
Soft® software.
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